|
Re: Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
|
7
|
Resverlogix Corp.
|
Aug 29, 2023 09:30AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
2
|
Resverlogix Corp.
|
Dec 22, 2020 12:04PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
2
|
Resverlogix Corp.
|
Dec 22, 2020 01:10PM
|
|
Re: Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
|
1
|
Resverlogix Corp.
|
Sep 23, 2019 11:19AM
|
|
Re: Resverlogix Announces Change in Fiscal Year-End to December 31
|
4
|
Resverlogix Corp.
|
Mar 14, 2021 07:16PM
|
|
Re: Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on
|
4
|
Resverlogix Corp.
|
Jun 06, 2020 08:04PM
|
|
Re: Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on
|
5
|
Resverlogix Corp.
|
Jun 06, 2020 08:53PM
|
|
Re: Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on
|
2
|
Resverlogix Corp.
|
Jun 07, 2020 11:56AM
|
|
Re: Resverlogix announces HEPALINK debenture $6mill
|
4
|
Resverlogix Corp.
|
May 05, 2021 10:24AM
|
|
Re: Resverlogix Announces Participation at Prominent Industry and Investor Conferences
|
2
|
Resverlogix Corp.
|
Mar 11, 2019 11:22AM
|
|
Re: RESVERLOGIX ANNOUNCES PROPOSED OFFERING OF UNITS April 17, 2018
|
3
|
Resverlogix Corp.
|
May 14, 2019 09:52PM
|
|
Re: RESVERLOGIX ANNOUNCES PROPOSED OFFERING OF UNITS April 17, 2018
|
1
|
Resverlogix Corp.
|
May 14, 2019 11:30PM
|
|
Re: Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
|
3
|
Resverlogix Corp.
|
Jan 11, 2024 09:26AM
|
|
Re: Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
|
2
|
Resverlogix Corp.
|
Jan 11, 2024 09:44AM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
3
|
Resverlogix Corp.
|
Mar 31, 2020 05:44PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
1
|
Resverlogix Corp.
|
Mar 31, 2020 06:32PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
3
|
Resverlogix Corp.
|
Mar 31, 2020 07:02PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
4
|
Resverlogix Corp.
|
Mar 31, 2020 07:56PM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
5
|
Resverlogix Corp.
|
Mar 31, 2020 08:07PM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
|
5
|
Resverlogix Corp.
|
Aug 04, 2020 08:38AM
|
